Health & Fitness
Mon, February 13, 2012Sun, February 12, 2012Fri, February 10, 2012Thu, February 9, 2012Wed, February 8, 2012Tue, February 7, 2012Mon, February 6, 2012Sun, February 5, 2012Sat, February 4, 2012Fri, February 3, 2012Thu, February 2, 2012Wed, February 1, 2012Tue, January 31, 2012Transcept Pharmaceuticals to Present at Two Upcoming Investor Conferences
//health-fitness.news-articles.net/content/2012/ .. resent-at-two-upcoming-investor-conferences.html
Published in Health and Fitness on Tuesday, February 7th 2012 at 5:11 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
Transcept Pharmaceuticals to Present at Two Upcoming Investor Conferences -- POINT RICHMOND, Calif., Feb. 7, 2012 /PRNewswire/ --
Transcept Pharmaceuticals to Present at Two Upcoming Investor Conferences
POINT RICHMOND, Calif., Feb. 7, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: [ TSPT ]), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present at two upcoming investor conferences.
Transcept management plans to present a general corporate overview at the:
BIO CEO and Investor Conference in New York on February 14, 2012, 9:00 a.m. ET; and
Leerink Swann Global Healthcare Conference in New York on February 15, 2012, 4:00 p.m. ET.
A live audio webcast of each presentation will be available in the investor relations section of the Transcept website at [ www.transcept.com ]. The archive of the presentation will be available there for approximately 30 days following the event.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience.
Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Transcept and Purdue are parties to a collaboration agreement for the development and commercialization of Intermezzo in the United States. Transcept holds all commercialization and development rights to Intermezzo outside North America and has co-promotion rights to Intermezzo in the United States.
As part of its product pipeline activities, Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder.
For information about Intermezzo, please visit [ www.intermezzorx.com ].
For further information about Transcept, please visit [ www.transcept.com ].
Contact:
Transcept Pharmaceuticals, Inc.
Greg Mann
Director, Corporate Communications
(510) 215-3567
[ gmann@transcept.com ]
SOURCE Transcept Pharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.transcept.com ]
